Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F13A1 | P00488 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | MPO | P05164 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29009751 | 1.00 | F13A1 (0.56) | F13A1MAPTRXFP1FFAR4FFAR1 | |
| SCHEMBL15808566 | 0.98 | F13A1 (0.53) | F13A1MAPTRXFP1FFAR4FFAR1 | |
| SCHEMBL6956901 | 0.95 | FFAR1 (0.50) | F13A1FFAR4FFAR1HDAC1HDAC7 | |
| SCHEMBL3914168 | 0.88 | MPO (0.48) | F13A1HDAC1HDAC7MPOMAOB | |
| SCHEMBL29009856 | 0.87 | F13A1 (0.56) | F13A1MAPTRXFP1FFAR4FFAR1 | |
| SCHEMBL2397247 | 0.86 | FFAR1 (0.59) | FFAR4FFAR1MAOBHTR2AHTR2C | |
| SCHEMBL30637597 | 0.86 | FFAR1 (0.59) | FFAR4FFAR1MAOBHTR2AHTR2C | |
| SCHEMBL6761646 | 0.85 | FFAR1 (0.42) | F13A1MAPTFFAR4FFAR1 | |
| SCHEMBL6761652 | 0.85 | FFAR1 (0.42) | F13A1MAPTFFAR4FFAR1 | |
| SCHEMBL8239860 | 0.85 | F13A1 (0.53) | F13A1MAPTRXFP1FFAR4FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10654880-B2 | Methods for preparation of glycosphingolipids and uses thereof | LIANG PI HUI (TW) | 2020-05-19 | — | — | US | disclosed |
| US-10654880-B2 | Methods for preparation of glycosphingolipids and uses thereof | LIANG PI HUI (TW) | 2020-05-19 | — | — | US | disclosed |
| EP-2661440-B1 | METHOD FOR THE PREPARATION OF GLYCOSPHINGOLIPIDS | UNIV NAT TAIWAN (TW) | 2017-09-27 | — | — | EP | disclosed |
| EP-2661440-B1 | METHOD FOR THE PREPARATION OF GLYCOSPHINGOLIPIDS | UNIV NAT TAIWAN (TW) | 2017-09-27 | — | — | EP | disclosed |
| US-20160229881-A1 | METHODS FOR PREPARATION OF GLYCOSPHINGOLIPIDS AND USES THEREOF | LIANG PI-HUI (TW) | 2016-08-11 | — | — | US | disclosed |
| US-20160229881-A1 | METHODS FOR PREPARATION OF GLYCOSPHINGOLIPIDS AND USES THEREOF | LIANG PI-HUI (TW) | 2016-08-11 | — | — | US | disclosed |
| US-20160229881-A1 | METHODS FOR PREPARATION OF GLYCOSPHINGOLIPIDS AND USES THEREOF | LIANG PI-HUI (TW) | 2016-08-11 | — | — | US | disclosed |
| US-9181292-B2 | Methods for preparation of glycosphingolipids and uses thereof | LIANG PI-HUI (TW) | 2015-11-10 | — | — | US | disclosed |
| US-9181292-B2 | Methods for preparation of glycosphingolipids and uses thereof | LIANG PI-HUI (TW) | 2015-11-10 | — | — | US | disclosed |
| US-9181292-B2 | Methods for preparation of glycosphingolipids and uses thereof | LIANG PI-HUI (TW) | 2015-11-10 | — | — | US | disclosed |
| EP-2661440-A2 | METHODS FOR PREPARATION OF GLYCOSPHINGOLIPIDS AND USES THEREOF | National Taiwan University (TW) | 2013-11-13 | — | — | EP | disclosed |
| US-20120178705-A1 | METHODS FOR PREPARATION OF GLYCOSPHINGOLIPIDS AND USES THEREOF | NATIONAL TAIWAN UNIVERSITY (TW) | 2012-07-12 | — | — | US | disclosed |
| US-20120178705-A1 | METHODS FOR PREPARATION OF GLYCOSPHINGOLIPIDS AND USES THEREOF | NATIONAL TAIWAN UNIVERSITY (TW) | 2012-07-12 | — | — | US | disclosed |
| US-20120178705-A1 | METHODS FOR PREPARATION OF GLYCOSPHINGOLIPIDS AND USES THEREOF | NATIONAL TAIWAN UNIVERSITY (TW) | 2012-07-12 | — | — | US | disclosed |
| WO-2012094540-A2 | METHODS FOR PREPARATION OF GLYCOSPHINGOLIPIDS AND USES THEREOF | NATIONAL TAIWAN UNIVERSITY (TW) | 2012-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178705-A1 | METHODS FOR PREPARATION OF GLYCOSPHINGOLIPIDS AND USES THEREOF | UGCG, CERS2, SGMS1 | F13A1 679/4885MAPT 2929/4885RXFP1 4469/4885 |
| US-20160229881-A1 | METHODS FOR PREPARATION OF GLYCOSPHINGOLIPIDS AND USES THEREOF | UGCG, CERS2, SGMS1 | F13A1 679/4885MAPT 2929/4885RXFP1 4469/4885 |
| US-10654880-B2 | Methods for preparation of glycosphingolipids and uses thereof | UGCG, CERS2, SGMS1 | F13A1 679/4885MAPT 2929/4885RXFP1 4469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.